Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 16/20 | 0.71 |
| ▸ | IMPDH1 | P20839 | 6/20 | 0.68 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5010873 | 0.93 | IMPDH2 (0.68) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL5010857 | 0.92 | IMPDH2 (0.67) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL5010852 | 0.89 | IMPDH2 (0.73) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1474041 | 0.87 | IMPDH2 (0.77) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL5010905 | 0.86 | IMPDH2 (0.66) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6486099 | 0.85 | IMPDH2 (0.67) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6499382 | 0.85 | IMPDH2 (0.64) | IMPDH2IMPDH1 | |
| SCHEMBL5013919 | 0.84 | IMPDH2 (0.74) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1473286 | 0.84 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1474188 | 0.84 | IMPDH2 (0.85) | IMPDH2IMPDH1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | claimed |
| EP-2803357-B1 | Angiogenesis inhibitors | UNIV JOHNS HOPKINS (US) | 2020-11-18 | — | — | EP | disclosed |
| US-9642865-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-8980930-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | UNIV JOHNS HOPKINS (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2803357-A2 | Angiogenesis inhibitors | THE JOHNS-HOPKINS UNIVERSITY (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20080193499-A1 | Angiogenesis Inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-14 | — | — | US | disclosed |
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885IMPDH1 2706/4885AAK1 793/4885 |
| US-20080193499-A1 | Angiogenesis Inhibitors | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885IMPDH1 2706/4885AAK1 793/4885 |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885IMPDH1 2706/4885AAK1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.